A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Male or female recipients of solid organ transplants

• Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis

• Currently on investigational drug everolimus (RAD) therapy

Exclusion Criteria:

• Inability or unwillingness to comply with immunosuppressive regimen.

• Pregnancy.

• History of acute organ rejection within the last 3 months.

Other protocol-defined inclusion/exclusion criteria may apply.